Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Joseph Greene

Child & Adolescent Psychiatry Monterey, CA Medical Doctor

NPI 1649471756 CMS profile 210267

415 Figueroa St, Monterey, CA 93940

Open in the dashboard

General payments

$2,631

135 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Joseph Greene of Monterey, CA is reported in the CMS Open Payments database as having received $2,631 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $533 21
2021 General $732 36
2020 General $359 15
2019 General $1,007 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Greene
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Joseph Greene were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Joseph Greene Child & Adolescent Psychiatry median Middle half National median
2019 $1,007 $129 $42–$419 $163
2020 $359 $81 $28–$226 $114
2021 $732 $115 $31–$326 $132
2022 $533 $124 $40–$382 $149
2023 $0 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $0 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sunovion Pharmaceuticals Inc. $541 25 payments
  2. AbbVie, Inc. $435 21 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $334 16 payments
  4. Janssen Pharmaceuticals, Inc $303 11 payments
  5. Otsuka America Pharmaceutical, Inc. $303 18 payments
  6. Allergan Inc. $264 19 payments
  7. Shire North American Group Inc $121 9 payments
  8. Supernus Pharmaceuticals, Inc. $103 5 payments
  9. Ironshore Pharmaceuticals Inc. $70 3 payments
  10. Lundbeck LLC $46 2 payments
  11. Other $112 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,631 135 payments
Products named General payments · program years 2019–2022
  1. LATUDA $541 25 payments
  2. VRAYLAR Neuroscience $435 21 payments
  3. REXULTI $303 18 payments
  4. TRINTELLIX $264 11 payments
  5. VRAYLAR Neuroscience $264 19 payments
  6. INVEGA SUSTENNA $233 8 payments
  7. SPRAVATO $186 7 payments
  8. VYVANSE $139 10 payments
  9. QELBREE $103 5 payments
  10. INVEGA TRINZA $64 2 payments
  11. Other $280 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record